Need support, need to talk? Call 1-800-243-7692
GMHC - Fight Aids. Love Life.

GMHC's Response to NHS England's Decision to Decline Commission of Prep








June 1, 2016
Contact: Anthony Hayes | 917-601-0410 |


New York, New York - GMHC released the following statement in response to NHS England's decision to decline to commission the HIV-prevention drug Pre-Exposure Prophylaxis (PrEP) that can reduce people's changes of being infected with HIV by up to 99 percent, if taken daily.


NHS England's decision to once again decline to commission PrEP, a drug endorsed by the World Health Organization and available in countries including the US, Canada, France, Kenya and Israel, is a step backward in the fight to end HIV and AIDS. PrEP is a tool that, when used in combination with traditional prevention techniques, can help curb the epidemic for good.

People should not be restricted from accessing this lifesaving tool, simply because of the country they live in. PrEP is a key part of New York State's vision for ending the epidemic by 2020, and GMHC is proud to support the widespread use of this tool - in the United States, and across the nation.  

#  #  #

About Gay Men's Health Crisis
Gay Men's Health Crisis (GMHC) is the nation's leading provider of HIV and AIDS care, prevention services and advocacy, serving nearly 9,000 people living with and affected by HIV and AIDS in New York City, the epidemic's largest U.S. epicenter. As the world's first HIV and AIDS service organization, GMHC is an expert in providing services that every person affected by the epidemic deserves. GMHC is on the front lines caring for people who are both HIV negative and positive, including: testing, nutrition, legal, mental health and education services. GMHC also advocates for stronger public policies at the local, state and federal level with the goal of ending AIDS as an epidemic in New York State by 2020. Most recently, GMHC and other HIV and AIDS organizations successfully persuaded the federal government to recommend widespread use of PrEP, a new daily treatment that is over 90% effective in preventing HIV infection. For more information, visit